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Abstract: Chronic constipation is highly prevalent, reduces patients’ quality of life, and imposes 
a signiﬁ  cant health care burden on society. Lifestyle modiﬁ  cations and over-the-counter agents 
improve symptoms of constipation in some patients, however many patients have persistent 
symptoms and require the use of prescription medications. Three prescription medications are 
currently Food and Drug Administration (FDA) approved and available for the treatment of 
chronic constipation in adults. This review will focus on lubiprostone, the newest medication 
available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite 
analogue of prostaglandin E1. It activates speciﬁ  c chloride channels in the gastrointestinal tract 
to stimulate intestinal ﬂ  uid secretion, increase gastrointestinal transit, and improve symptoms 
of constipation. This article will provide a brief overview on chloride channel function in the 
gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, 
and discuss the safety and efﬁ  cacy of this new medication.
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Introduction
Constipation is a common disorder with an estimated prevalence of approximately 
15% in the United States (Higgins and Johanson 2004). Women are affected more 
commonly than men, although the mechanism that accounts for this disparity has not 
been identiﬁ  ed. Constipation is also more prevalent in the elderly, in non-Caucasians, 
and in patients in lower socioeconomic classes (Higgins and Johanson 2004; Lacy and 
Cole 2004). Although the natural history of chronic constipation is not as well studied 
as other common functional bowel disorders such as dyspepsia and irritable bowel 
syndrome (IBS), most patients with chronic constipation remain symptomatic when 
surveyed 18–20 months after initial evaluation (Talley et al 1992).
Although not a life-threatening illness, chronic constipation markedly affects 
patients’ quality of life and imposes a signiﬁ  cant economic burden to the health care 
system. Using the well-validated SF-36 questionnaire, several studies have shown 
that patients with chronic constipation note a reduction in quality of life across mul-
tiple domains, including both physical and psychological domains (Irvine et al 2002; 
Dennison et al 2005). The costs associated with treating chronic constipation arise 
due to both indirect and direct costs. Indirect costs include missing school or work 
(absenteeism) and being less productive at school or work (presenteeism), while the 
direct costs of treating constipation include ofﬁ  ce visits, diagnostic tests, and medica-
tions. Overall, it is estimated that several billion dollars are spent each year in the US 
treating chronic constipation (Irvine et al 2002).
The deﬁ  nition of constipation has evolved over the last decade and is currently 
based on symptoms rather than stool frequency alone. Patients with constipation often 
describe a constellation of symptoms that includes infrequent stools, straining, feelings Clinical Interventions in Aging 2008:3(2) 358
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of incomplete evacuation, and rectal or perianal fullness or 
discomfort. The recently released Rome III criteria have 
attempted to take these various symptoms into consideration 
(Longstreth et al 2006; see Table 1). Pathophysiologically, 
constipation is generally classiﬁ  ed as either primary (eg, 
colonic inertia, pelvic ﬂ  oor dysfunction, normal transit 
constipation, IBS with constipation) or secondary in nature 
(eg, metabolic, endocrine, surgical, psychiatric) (see Table 2; 
Longstreth et al 2006; Brandt et al 2005).
Treating patients with constipation can be frustrating at 
times, because symptoms do not always accurately reﬂ  ect 
the underlying pathophysiology nor do they predict response 
to treatment. Many patients initially self-treat with life-style 
modiﬁ  cations, which include drinking more water, exercis-
ing, and adding dietary ﬁ  ber. Although these treatments 
are safe, they are usually ineffective except in patients who 
are ﬁ  ber deﬁ  cient (Young et al 1998; Muller-Lissner et al 
2005). Patients with persistent symptoms then generally use 
over-the-counter medications, which include bulk laxatives 
(eg, psyllium), osmotic laxatives (eg, magnesium citrate), 
emollients (eg, docusate sodium), and stimulant laxatives 
(eg, cascara). Although some patients note an improvement 
in symptoms, there is little evidence documenting long-term 
clinical efﬁ  cacy of these agents (Brandt et al 2005). Symp-
toms that fail to respond to this step-wise approach generally 
lead a patient to seek medical consultation. After an appropri-
ate evaluation has been performed, medical therapy is usually 
recommended, and this may include osmotic agents (eg, 
polyethylene glycol, lactulose) or a chloride type 2 channel 
activator (eg, lubiprostone).
The efﬁ  cacy of polyethylene glycol (PEG) for chronic 
constipation (deﬁ  ned as symptoms for at least six months) 
compared to placebo was recently studied by DiPalma 
and colleagues (DiPalma et al 2007). PEG relieved symptoms 
of chronic constipation (modiﬁ  ed Rome criteria) more than 
half the time in 52% of subjects, while placebo was effective 
in 11% of subjects (p  0.001). Forty percent of patients tak-
ing PEG experienced gastrointestinal side effects (abdominal 
distension, diarrhea, loose stools, ﬂ  atulence, and nausea) 
compared to 25% in the placebo group (p = 0.015). None of 
these effects were individually statistically signiﬁ  cant, and no 
differences in emergent adverse events were observed among 
elderly patients. The safety and efﬁ  cacy of other osmotic 
agents has been discussed in two recent monographs and will 
not be reviewed further (Brandt et al 2005; Cash et al 2006). 
The remainder of this review will focus on lubiprostone.
Chloride channels
Chloride channels are found throughout the body in virtually 
all cell types (Chen 2005). They are pore-forming proteins that 
allow the transport of chloride ions across cell membranes. In the 
gastrointestinal (GI) tract, a number of different chloride chan-
nels play a critical role in ﬂ  uid transport, and the maintenance 
of both cell volume and intracellular pH (Suzuki et al 2006). 
At present, 9 separate chloride channels (abbreviated ClC) have 
been identiﬁ  ed (ClC-0 – ClC7, ClC-Ka, ClC-Kb). This review, 
however, will focus on the ClC-2 channel, since this chloride 
channel is the one selectively activated by lubiprostone.
The ClC-2 channel is distributed throughout the GI tract, 
including the stomach, small intestine, and colon. It is a 
transmembrane protein that is highly selective for Cl- and 
is not permeable to larger anions or to cations (Mindell and 
Maduke 2001). ClC-2 channels are localized to the apical cell 
membrane in human intestine (Lipecka et al 2002).
Key properties of lubiprostone
Structure
The formal chemical name of lubiprostone is diﬂ  uoropentyl-
2-hydroxy-6-oxooctahydrocyclopenta-heptanoic acid 
Table 1 Rome III criteria for chronic constipation
- Symptom onset at least 6 months prior to diagnosis
- Presence of symptoms for the last 3 months (see below)
- Insufﬁ  cient criteria for IBS
- Loose stools are rarely present without the use of laxatives
-   Symptoms include 2 or more of the following during at least 25% 
of defecations:
¶ Straining
¶ Lumpy or hard stools
¶ Sensation of incomplete evacuation
¶ Sensation of anorectal obstruction or blockade
¶ Manual maneuvers to facilitate evacuation
¶ Less than 3 bowel movements per week
Modiﬁ  ed with permission from Longstreth GF, Thompson WG, Chey WD, et al. 2006. 
Functional bowel disorders. Gastroenterology, 130:1480–91. Copyright © 2006 Elsevier.
Abbreviation: IBS, irritable bowel syndrome.
Table 2 Common causes of constipation
Primary
  Slow transit constipation
 Pelvic  ﬂ  oor dyssynergia
  Irritable bowel syndrome with constipation
  Normal transit constipation
Secondary
 Anatomical  obstruction
 Medications
 Metabolic  disorders
 Neurologic/myopathic  disorders
  Psychiatric (somatization, anxiety, depression)
 IdiopathicClinical Interventions in Aging 2008:3(2) 359
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(Amitiza® Package Insert). It is a white, odorless crystal 
and powder that is insoluble in water but soluble in ethanol. 
Lubiprostone is classiﬁ  ed as a prostone, a bicyclic fatty 
acid compound derived from a metabolite of prostaglandin 
E1. Lubiprostone can tautomerize between two different 
forms – II is the active form (see Figure 1).
Pharmacokinetics and metabolism
The pharmacokinetic properties of lubiprostone were 
evaluated in a study of fasted healthy male volunteers 
(Amitiza® Package Insert). After ingesting a single 
72 microgram dose of radio-labeled lubiprostone, 60% of the 
radio-label was recovered in the urine within 24 hours, and 
63% was recovered in the urine by the end of one week. Thirty 
percent of the total administered radioactivity was recovered 
in the stool by one week. The parent molecule cannot be 
detected in plasma, urine, or stool, and it is thought that the 
measured radioactivity represents the active metabolite, M3. 
Peak plasma levels occur approximately 1.14 hours after oral 
administration of a single 24 microgram dose, and the half-
life of lubiprostone (t½) has been estimated at approximately 
3 hours (Amitiza® Package Insert).
Metabolism takes place within the GI tract via 
microsomal carbonyl reductase; the cytochrome P450 
system is not involved. In contrast to the parent drug, M3 is 
absorbed and approximately 94% is bound to human plasma 
proteins. The half-life of M3 is approximately 0.9–1.4 hours. 
Although not tested in large studies, gender does not appear 
to inﬂ  uence the metabolism of lubiprostone. No studies 
have been conducted to assess the pharmacokinetic proﬁ  le 
of lubiprostone in patients with hepatic or renal impairment. 
In summary, lubiprostone appears to act locally within 
the GI tract, has a fairly quick onset of action, is rapidly 
metabolized on the cell surface, and thus should have few 
drug-drug interactions.
Mechanism of action
Lubiprostone speciﬁ  cally activates ClC-2 channels on the 
apical membrane of epithelial cells (Cuppoletti et al 2004). 
Highly speciﬁ  c inhibitors of ClC-2 channels are not avail-
able, and thus appropriate blocking experiments cannot be 
performed. Activation of ClC-2 channels causes an efﬂ  ux of 
chloride into the lumen of the GI tract, followed by an efﬂ  ux 
of sodium ions in order to maintain isoelectric neutrality. It 
should be noted that sodium efﬂ  ux does not occur through 
the apical membrane but rather occurs through a paracellular 
pathway. Water then follows along the paracellular pathway 
in order to maintain isotonic equilibrium. Animal studies have 
demonstrated that administration of lubiprostone increased 
intestinal ﬂ  uid secretion in a dose-dependent manner com-
pared to vehicle (Ueno et al 2004). Animal studies have also 
demonstrated that lubiprostone does not appear to have a 
direct stimulatory effect on gastrointestinal smooth muscle 
(Perentesis et al 2005).
In summary, lubiprostone stimulates ClC-2 channels and 
promotes intestinal ﬂ  uid secretion. The secretion of ﬂ  uids 
into the GI tract adds ﬂ  uid to stool and promotes increased 
transit, likely through stimulation of local receptors sensitive 
to stretch and distention (Grider and Jin 1994; Camilleri et al 
2006). Lubiprostone does not appear to have any signiﬁ  cant 
activity on smooth muscle or on prostaglandin receptors.
Effects on reproduction and development
In animal models, lubiprostone does not appear to have direct 
teratogenic effects (Amitiza® Package Insert; Crawford et al 
2005). However, administration of lubiprostone at 6-10 times 
the recommended level was associated with an increased rate 
of fetal loss in a guinea pig model. This was not felt to be a 
direct effect, but rather was thought to occur secondary to 
weight loss in the pregnant animals (Amitiza® Package Insert; 
Crawford et al 2005). Fetal loss did not occur in similarly 
Figure 1 Structure of lubiprostone.Clinical Interventions in Aging 2008:3(2) 360
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designed experiments involving mice and rats. Due to the 
adverse effects observed in the guinea pig model and the lack 
of well-controlled studies in pregnant women, lubiprostone is 
accordingly rated a pregnancy category “C” by the FDA.
Clinical studies
The efﬁ  cacy of lubiprostone for the treatment of constipa-
tion has been studied in a recently published double-blind, 
placebo-controlled dose ranging study, two separate phase 
3 trials, a withdrawal study, and several larger open-label 
studies.
Randomized controlled trials
The dose-ranging study to evaluate the efﬁ  cacy and safety of 
lubiprostone involved 129 subjects with symptoms of chronic 
(at least 6 months) constipation (Johanson and Ueno 2007). 
Constipation was deﬁ  ned as fewer than 3 spontaneous bowel 
movements (SBM) per week, together with one or more of the 
following symptoms occurring at least 25% of the time: hard 
stools, straining, or feelings of incomplete evacuation. The 
subjects received either lubiprostone (24, 48, or 72 µg/day) 
or placebo for 3 consecutive weeks after a 2-week washout 
period. The patients were predominantly female (84% in 
each treatment arm) and Caucasian (81% in each treatment 
arm). The mean age was 48.3 years with 10% of patients 
being at least 65 years of age. Patients in the treatment groups 
had a signiﬁ  cant increase in the average number of weekly 
SBMs during the ﬁ  rst (p = 0.006) and second week of the 
study (p = 0.014), and over the entire study period (p = 0.046) 
when compared to placebo. Each of the three treatment arms 
showed signiﬁ  cant improvement in SBM frequency at week 2 
of the study compared with placebo (p  0.020), but only 
the 48 µg treatment group showed a statistically signiﬁ  cant 
improvement over the entire treatment period (p = 0.015). 
A larger percentage of patients in each treatment arm had a 
SBM within 24 hours of initial dosing of lubiprostone com-
pared to placebo; the difference for the two highest dosing 
groups was statistically signiﬁ  cant (placebo group = 27.3%; 
24 µg group = 44.8%, 48 µg = 59.4%; (p = 0.009); 
72 µg = 63.6%; p = 0.003). Several measures of constipation 
were assessed each week during the trial period using 4 and 
5 point scales. The lubiprostone treatment group experienced 
a statistically signiﬁ  cant improvement over the entire treat-
ment period when compared to baseline in the mean degree 
of straining (p  0.005), stool consistency (p  0.0001), 
abdominal bloating (p = 0.035), severity of constipation 
(p = 0.010), and overall rating of treatment effectiveness 
(p = 0.045). Abdominal discomfort also improved but did 
not reach statistical signiﬁ  cance (p = 0.136).
There were no drug-related serious adverse events 
during the trial. Clinical assessments including hematol-
ogy, blood chemistries, vital signs, physical examination, 
and electrocardiogram (ECG) showed no clinically signiﬁ  -
cant trends during the study. One patient in each treatment 
group had a QT change of 30–60 seconds on ECG from 
baseline, which was considered non-speciﬁ  c. Sixty-nine 
percent of patients in the lubiprostone group experienced at 
least one adverse event compared to 39% of patients taking 
placebo. Adverse events of severe intensity were reported 
by 12 (9%) patients. Of these events, 10 were experienced 
by more than 1 patient and included: headache (2 patients 
in the 72 µg arm), diarrhea (4 patients in the 72 µg arm), 
abdominal pain (1 patient in the placebo arm and 1 patient 
in the 48 µg group), and nausea (1 patient in each of the 
lubiprostone 48 µg and 72 µg groups). Nausea was the most 
common adverse event. No patients taking placebo reported 
nausea, but it was reported by 17% of the 24 µg group, 
43.8% of the 48 µg, and 36.4% of the 72 µg group. Nausea 
in each of the patients except one (30/31) was judged to be 
related to the medication by the investigator. Four percent 
of study patients discontinued the study because of nausea. 
The mechanism underlying the development of nausea in 
patients treated with lubiprostone is not known.
Data from two similar phase III multi-center trials reinforce 
the ﬁ  ndings of the initial dose-ranging study (Johanson et al 
2005a; Johanson et al 2008). Inclusion criteria required that 
patients have symptoms of chronic constipation as previously 
described (Johanson and Ueno 2007). One trial involved 242 
subjects (mean age = 48.6 years; 90% women; 13%  65 years 
age) from 20 centers across the US (Johanson et al 2008). After 
a 2-week baseline period, lubiprostone (24 µg) or placebo was 
administered twice daily for 4 weeks. Patients were prohib-
ited from using prescription or over-the-counter constipation 
remedies during the washout and study periods. Dulcolax® 
suppositories or Fleet® enemas were authorized by the study 
investigators as “rescue” therapy for those subjects without 
Table 3 Key properties of lubiprostone
Recommended dosage  24 µg twice daily
Route of administration  Oral
Time to peak plasma concentration  Approximately 1.5 hours
Estimated terminal half-life  Approximately 3 hours
Bioavailability  1%
Metabolite  M3 – partially active
Metabolism Carbonyl  reductase
Pregnancy category  CClinical Interventions in Aging 2008:3(2) 361
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a BM for 3 or more consecutive days. Compared to placebo, 
the treatment group had more SBMs during week 1 (5.69 vs 
3.46, p = 0.0001), and the effect was sustained during each 
of the subsequent weeks of the study. A larger percentage of 
patients on lubiprostone had an SBM within 24 hours (56.7% 
vs 36.9%, p = 0.0024) and within 48 hours (80.0% vs 60.7%, 
p = 0.0013). The need for rescue medications was similar 
in both groups at baseline but decreased in the lubiprostone 
group by the end of the study period (35.6% vs 50.8%, 
p = 0.0357). Symptom scores were signiﬁ  cantly improved 
with lubiprostone compared to placebo for weeks 1–4 for 
stool consistency (p  0.0001), straining (p  0.0001), and 
constipation severity (p  0.0003). Abdominal bloating 
was improved in the lubiprostone treated group compared 
to placebo during weeks 1–2 (p  0.031), while abdominal 
discomfort scores were signiﬁ  cantly improved for weeks 
2–4 (p  0.045). Seventy percent of subjects on lubipros-
tone reported at least one adverse event compared to 50.8% 
of patients on lubiprostone (p = 0.0026). Six percent of 
events were severe, but there was no signiﬁ  cant difference 
in incidence between treatment groups. The most common 
treatment-related adverse event was nausea, occurring in 
31.7% of the lubiprostone group and 3.3% of the placebo 
group (p  0.001). Five percent of patients discontinued the 
study due to nausea.
The second phase III trial included 237 subjects (mean 
age = 45.8 years; 88% women) (Johanson et al 2005a). 
Patients on lubiprostone experienced signiﬁ  cant improve-
ment in the frequency of weekly bowel movements (5.89 vs 
3.99, p  0.0001). Similar to the previously described studies, 
patients on lubiprostone reported improvements in subjective 
measures of constipation, and more patients experienced 
a SBM within the ﬁ  rst 24 hours in the lubiprostone group 
than the placebo group (61% vs 31%, p  0.0001). Nausea, 
headache, and diarrhea were again the most commonly 
reported adverse effects. Mild to moderate nausea occurred 
more frequently in the lubiprostone treated group than in the 
placebo group in the second study (21% vs 4.2%; p value not 
reported) (Johanson et al 2005b). No serious adverse events 
were reported; 15 lubiprostone patients withdrew from the 
second trial.
The potential for rebound constipation developing 
following drug withdrawal (after 4 weeks of lubiprostone 
treatment) was evaluated in 128 subjects (mean age and 
gender not reported) with chronic constipation, as previ-
ously deﬁ  ned (Johanson et al 2004). Lubiprostone (24 µg) 
was administered twice daily for 4 weeks after a 2-week 
washout period. Subjects were then randomized to receive 
3 additional weeks of lubiprostone or placebo. A rapid and 
sustained improvement in SBM similar to that seen in the 
other trials was observed (1.36 per week at baseline vs 6.25, 
5.94, and 5.52 at weeks 1, 2, and 3. respectively; p  0.0001 
at all weeks). Three weeks after randomization to placebo or 
to continued lubiprostone, the SBM frequency declined in 
the placebo group (3.04 vs 5.59; p = 0.0464) but remained 
improved compared to baseline (3.04 vs 1.36; p = 0.0223), 
arguing against signiﬁ  cant rebound constipation after lubi-
prostone withdrawal.
Open-label studies
Three large, open-label studies investigated the long-term 
efﬁ  cacy of lubiprostone using ﬁ  ve point scales as a subjec-
tive measure of constipation. The severity of constipation, 
bloating, and abdominal discomfort were periodically 
assessed among 880 patients (308 patients were entered 
into one 24-week study; a total of 572 patients were entered 
into 2 separate 48-week trials) (Johanson et al 2006a). There 
were statistically signiﬁ  cant improvements in all symptoms 
throughout the trial periods (p  0.0001). Assessments of 
constipation severity improved across all three studies by 
an average of 26% at weeks 4–6 (n = 28), 29% at week 24 
(n = 512), and 28% at week 48 (n = 281). Bloating improved 
by an average of 18% at weeks 4–6 (n = 829), and 20% at 
both 24 weeks (n = 512) and 48 weeks (n = 282). Abdomi-
nal discomfort improved by an average of 15% at week 1 
(n = 619), 18% at 24 weeks (n = 512), and 17% at 48 weeks 
(n = 282).
Women comprised the majority of subjects in the initial 
trials of lubiprostone. A subgroup analysis of the four-week 
controlled trials was performed to evaluate efﬁ  cacy in men 
(Ueno et al 2006a). Pooled data yielded 27 male placebo 
subjects and 32 lubiprostone subjects. Male subjects taking 
lubiprostone experienced 5.69–6.05 SBMs per week com-
pared to 2.55–3.23 in the placebo group (p  0.0489 at week 
3, p = 0.0503 at week 4). These rates were higher compared 
to females in the trials (4.99–5.75 SBM/week). Fifty percent 
of male subjects taking lubiprostone experienced at least one 
side effect compared to 33.3% of men taking placebo (details 
of adverse effects were not reported).
Lubiprostone use in elderly patients
Analysis of the clinical trials performed to date provides 
insight into the safety and efﬁ  cacy of lubiprostone in elderly 
subjects (deﬁ  ned as 65 years old). Pooled data from 3 of 
the previously described 4-week controlled trials yielded 
31 elderly patients in the placebo groups and 26 patients in Clinical Interventions in Aging 2008:3(2) 362
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the lubiprostone groups (Ueno et al 2006b). Improvements 
in SBM per week, during each of the 4 weeks, ranged from 
4.6–5.4 in the lubiprostone treated group compared to 
1.29–2.27 for those treated with placebo (p  0.0286). Fewer 
adverse events were reported in elderly subjects treated with 
lubiprostone compared to subjects treated with placebo (46% 
vs 61%; p value not reported). In a subgroup analysis of the 
open-label trials, pooled data yielded 163 elderly subjects 
(65 years old) and 715 non-elderly subjects (Ueno et al 
2006c). Fewer elderly patients reported adverse effects when 
treated with lubiprostone compared to non-elderly subjects 
(74.2% vs 80.1%; p value not reported). The most common 
side effect, nausea, was less common among elderly subjects 
than younger patients (17.8% vs 29.4%; p value not reported). 
In summary, despite the smaller total number of elderly 
patients, analysis of pooled data indicates that lubiprostone 
is both effective and safe in the treatment of constipation in 
the elderly.
Adverse effects and safety
One study of 26 healthy volunteers was designed to spe-
ciﬁ  cally evaluate the safety and tolerability of lubiprostone 
(Ueno 2005). Subjects in each group received either placebo 
or one of three doses of lubiprostone (72 µg, 90 µg, or 108 µg 
divided into 3 daily doses). The subjects were monitored 
closely for 7 days without any changes in electrocardiograms, 
laboratory testing, or vital signs. There were no serious 
adverse events. Two subjects who withdrew from the study 
did so voluntarily and had no adverse events. Almost all of 
the adverse events consisted of gastrointestinal symptoms 
including vomiting, nausea, and abdominal cramping. As 
expected, subjects receiving lubiprostone experienced more 
diarrhea than those on placebo. The effect did not seem to 
be dose dependent.
Pooled data from previously mentioned studies, including 
258 patients from 2 blinded studies and 858 patients from 3 
open-label trials, were reviewed for a change in serum elec-
trolytes due to lubiprostone (24 µg bid) (Rivera et al 2007). 
In the blinded and open-label trials, 10.5% and 18.6% of 
patients respectively were 65 years of age or greater. There 
were no changes in electrolytes observed over the treatment 
period, which ranged from 12 to 48 weeks.
ECG changes due to lubiprostone were evaluated in 
177 patients with chronic constipation and 68 healthy male 
and female volunteers (age was not reported) (Sprenger 
et al 2007). ECGs before and after a single dose of 24 µg 
lubiprostone or a supratherapeutic dose of 144 µg did not 
show any changes.
We do not recommend using lubiprostone during pregnancy 
due to the lack of human reproductive data, and the manufactur-
ers have recommended using lubiprostone during pregnancy 
only if the beneﬁ  ts signiﬁ  cantly outweigh potential risks. Prior 
to initiating therapy, a pregnancy test should be checked in all 
women of child-bearing age not using a reliable form of birth 
control. Given the limited data available, we also do not recom-
mend using lubiprostone in women who are breastfeeding.
Other potential uses
Irritable bowel syndrome 
with constipation
The results of the ﬁ  rst phase III study evaluating the safety 
and efﬁ  cacy of lubiprostone in patients with IBS and consti-
pation were recently published in abstract form (Drossman 
et al 2007). Earlier phase II dose-ranging studies had deter-
mined that 8 mcg of lubiprostone twice daily improved IBS 
symptoms (Johanson et al 2006b). However, the sample size 
was quite small. In the current study 1171 adults diagnosed 
with IBS-C using the Rome II criteria were randomized to 
receive either 12 weeks of twice daily lubiprostone (8 µg) or 
placebo. Most patients were women (91.6%), and most were 
between the ages of 18 and 65 (91.7%). The primary efﬁ  cacy 
variable was a global question rating overall IBS symptoms, 
while a 7-point balanced scale was used to rate changes in 
individual symptoms. Patients reporting at least moderate 
relief for 4 out of 4 weeks, or patients reporting signiﬁ  cant 
relief 2 out of 4 weeks were considered monthly responders, 
and patients had to be a monthly responder for at least 2 out 
of the 3 months in order to qualify as an overall responder. 
The authors reported that patients receiving lubiprostone were 
nearly twice as likely as those receiving placebo to achieve 
overall response (17.9% vs 10.1%; p = 0.001). Secondary 
endpoints, including abdominal pain, bloating, straining, stool 
consistency, and constipation were all signiﬁ  cantly improved 
in the lubiprostone group compared to the placebo group (p 
 0.05 for all endpoints). Lubiprostone was generally well 
tolerated. The most common treatment related side effects 
were nausea (8% vs 4% in placebo) and diarrhea (6% vs 4% 
in placebo). Of note, it is thought that the low placebo rate in 
this study is due to the much stricter standards for determining 
whether a patient is classiﬁ  ed as a responder. Also, the lower 
dose (8 µg) was chosen based on prior dose-ranging studies 
and may reﬂ  ect the fact that patients with IBS often respond 
to medications at lower doses than other patients. Further trials 
are planned to assess the long-term beneﬁ  ts of lubiprostone 
in patients with IBS and constipation.Clinical Interventions in Aging 2008:3(2) 363
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Opioid-induced constipation
Constipation is a frequent side effect of opioid use. Studies 
to evaluate the efﬁ  cacy and safety of lubiprostone in opioid-
induced constipation in humans have begun, although data 
are not yet available. Lubiprostone does appear to improve 
opioid-induced constipation in a mouse model, however 
(Ueno et al 2006d).
Summary
Chronic constipation is a highly prevalent disorder that is fre-
quently resistant to treatment with lifestyle modiﬁ  cations and 
over-the-counter remedies. Treatment options with prescription 
medications are limited, especially given the recent withdrawal 
of tegaserod from the marketplace (Zelnorm 2007). Lubipros-
tone, a new class of medication approved for the treatment of 
chronic constipation in both men and women (age 18 and over), 
was approved by the FDA on January 31, 2006 and is marketed 
under the trade name Amitiza®. It is available in a gelatin cap-
sule and the recommended dosing is 24 µg p.o. twice daily. 
No restrictions have been placed on the length of its use.
Lubiprostone selectively stimulates type 2 chloride chan-
nels in epithelial cells thereby causing an efﬂ  ux of chloride 
into the intestinal lumen. The resultant ﬂ  uid secretion into the 
gastrointestinal lumen provides a bolus effect that softens stool, 
increases intestinal transit, and improves symptoms of constipa-
tion. Lubiprostone acts locally within the intestinal tract, is rap-
idly metabolized, and has very low systemic bioavailability.
Preclinical trials have shown high speciﬁ  city of the drug 
for ClC-2 channels. Animal studies have shown that lubi-
prostone signiﬁ  cantly increases small intestinal ﬂ  uid volume 
and also elevates intestinal ﬂ  uid chloride concentration 
without altering serum electrolyte concentrations. Double-
blinded, randomized human studies have demonstrated that 
lubiprostone accelerates small bowel and colonic transit. 
Well-designed clinical trials and larger open-label trials 
have established lubiprostone as a safe and effective treat-
ment option for chronic constipation that is generally well-
tolerated. Future studies will determine its utility in other 
functional bowel disorders, especially opioid-induced con-
stipation and irritable bowel syndrome with constipation.
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